Posterior keratocyte density correlated with ectasia

Article

Posterior keratocyte density measurements could be a means of following eyes with post-LASIK ectasia, according to study results presented at this year's meeting of the American Academy of Ophthalmology (AAO).

Posterior keratocyte density measurements could be a means of following eyes with post-LASIK ectasia, according to study results presented at this year's meeting of the American Academy of Ophthalmology (AAO).

Maria A. Woodward, MD, a third-year ophthalmology resident at Emory University School of Medicine and Emory Vision, Atlanta, US, and colleagues conducted a post-LASIK ectasia keratocyte density study, with the hypothesis that keratocyte density may be diminished focally in the setting of post-LASIK corneal ectasia and that decreased keratocyte density may contribute to the development and progression of ectasia.

In the case-control study, the team performed histopathologic analysis on five corneal specimens with post-LASIK ectasia and five normal post-LASIK specimens, measuring keratocyte density by cell counts per high power field (C/HPF). Those specimens were evaluated with DAPI stain. Confocal microscopic analysis was performed in vivo on five ectatic and five normal eyes during patient evaluations. Analysis was performed by masked observers.

In ectasia cases, there was 49% less posterior keratocyte density by DAPI measurements in the ectatic regions; density was 16 C/HPF in the ectasia cases versus 23 C/HPF in the normal post-LASIK cases. Results of the confocal analysis also showed a statistically significant difference. The ectatic eyes had 30% less posterior keratocyte density than the normal eyes (30 versus 58 C/HPF).

The study investigators concluded that the decreased keratocyte density in the ectatic regions of the posterior stroma may contribute to the development of ectasia.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.